Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03635073 · ClinicalTrials.gov registry record · Phase 2
A Study of Soticlestat in Adults and Children With Rare Epilepsies
A Phase 2 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 2
- Development phase
- 156
- Enrollment target
NCT03635073 is a Phase 2 study that was terminated before completion, run by Takeda. The registered enrollment target is 156 participants.
The verdict
NCT03635073, a Phase 2 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 156 participants
- Enrollment target
Study Summary
The main aim is to assess the long-term safety and tolerability of soticlestat when used along with other anti-seizure treatment. Participants will receive soticlestat twice a day. Participants will visit the study clinic every 2-6 months throughout the study. Study treatments may continue as long as the participant is receiving benefit from it.
Interventions
- DRUG Soticlestat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2018-07-19 |
| Est. Completion | 2025-07-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03635073
The ClinicalTrials.gov registry entry for NCT03635073 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Soticlestat is the first listed.
NCT03635073 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03635073 about?
NCT03635073 is a clinical study titled "A Study of Soticlestat in Adults and Children With Rare Epilepsies". The main aim is to assess the long-term safety and tolerability of soticlestat when used along with other anti-seizure treatment. Participants will receive soticlestat twice a day. Participants will visit the study clinic every 2-6 months throughout the study. Study treatments may continue as long...
What is the current status of trial NCT03635073?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 156 participants. The study started on 2018-07-19. Estimated completion is 2025-07-30.
What interventions are being tested in trial NCT03635073?
The interventions under investigation include: Soticlestat (DRUG).
Who is sponsoring clinical trial NCT03635073?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.